Advertisement

Breast Cancer Research and Treatment

, Volume 15, Issue 1, pp 3–11 | Cite as

Autocrine and paracrine growth regulation of breast cancer: Clinical implications

  • C. Kent Osborne
  • Carlos L. Arteaga
11th San Antonio Breast Cancer Symposium — Plenary lecture

Summary

Research using experimental models of human breast cancer has broadened our understanding of the possible biochemical pathways regulating breast cancer growth. Breast cancer cells express receptors for and respond to a variety of steroid and polypeptide hormones and growth factors. Specific oncogenes are also expressed in breast cancer cells, and levels of expression may relate to tumor growth and aggressiveness. Recent studies have shown that breast cancer cells can even synthesize and secrete various growth factors that could stimulate tumor growth through autocrine and/or paracrine mechanisms. Secretion of some of these growth factors is regulated by estrogen, providing a possible mechanism for estrogen induced growth. Knowledge of these growth regulatory pathways has potentially important clinical implications. Blockade of these pathways offers new possible treatment strategies, much as antiestrogens have been used to inhibit tumor growth. Quantification of the expression of certain oncogenes, growth factor receptors, or the growth factors themselves, may provide prognostic information for the individual patient. Finally, it is plausible that measurement of these tumor products in body fluids might provide tumor markers that are useful in the diagnosis and treatment of breast cancer.

Key words

breast cancer growth factors growth regulation estrogen action 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Welsch CW, Nagasawa H: Prolactin and murine mammary tumorigenesis: A review. Cancer Res 37: 951–963, 1977PubMedGoogle Scholar
  2. 2.
    Lippman M, Monaco ME, Bolan G: Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 37: 1901–1907, 1977PubMedGoogle Scholar
  3. 3.
    Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff K, Kasid A: Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J Cell Biochem 35: 1–16, 1987PubMedGoogle Scholar
  4. 4.
    Ikeda T, Danielpour D, Sirbasku DA: Characterization of a sheep pituitary-derived growth factor for rat and human mammary tumor cells. J Cell Biochem 25: 213–229, 1984PubMedGoogle Scholar
  5. 5.
    Osborne CK, Bolan G, Monaco ME, Lippman ME: Hormone responsive human breast cancer in long term tissue culture: Effect of insulin. Proc Natl Acad Sci USA 73: 4536–4540, 1976PubMedGoogle Scholar
  6. 6.
    Osborne CK, Monaco ME, Lippman ME, Kahn CR: Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res 38: 94–102, 1978PubMedGoogle Scholar
  7. 7.
    Furlanetto RW, DiCarlo JN: Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res 44: 2122–2128, 1984PubMedGoogle Scholar
  8. 8.
    Pekonen F, Partanen S, Mäkinen T, Rutanen E-M: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343–1347, 1988PubMedGoogle Scholar
  9. 9.
    Karey KP, Sirbasku DA: Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res 48: 4083–4092, 1988PubMedGoogle Scholar
  10. 10.
    Coronado E, Ramasharma K, Li CH, Kitten L, Marshall M, Fuqua S, Osborne K: Insulin-like growth factor II (IGF-II): A potential autocrine growth factor for human breast cancer (Abstract). Proc Am Assoc Cancer Res 29: 237, 1988Google Scholar
  11. 11.
    Osborne CK, Hamilton B, Titus G, Livingston RB: Epidermal growth factor stimulation of human breast cancer cells in tissue culture. Cancer Res 40: 2361–2366, 1980PubMedGoogle Scholar
  12. 12.
    Osborne CK, Hamilton B, Nover M: Receptor binding and processing of epidermal growth factor by human breast cancer cells. J Clin Endo Metab 55: 86–93, 1982Google Scholar
  13. 13.
    Arteaga CL, Coronado E, Osborne CK: Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 2: 1064–1069, 1988PubMedGoogle Scholar
  14. 14.
    Huff KK, Knabbe C, Lindsey R, Kaufman D, Bronzert D, Lippman ME, Dickson RB: Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Mol Endocrinol 2: 200–208, 1988PubMedGoogle Scholar
  15. 15.
    Nunez A-M, Jakowlev S, Briand J-P, Gaire M, Krust A, Rio M-C, Chambon P: Characterization of the estrogeninduced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinol 121: 1759–1765, 1987Google Scholar
  16. 16.
    Peres R, Betsholtz C, Westermark B, Heldin C-H: Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines. Cancer Res 47: 3425–3429, 1987PubMedGoogle Scholar
  17. 17.
    Rochefort H, Capony F, Garcia M, Vacaillés V, Freiss G, Chambon M, Morisset M, Vignon F: Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J Cell Biochem 35: 17–29, 1987PubMedGoogle Scholar
  18. 18.
    Salomon DS, Zwiebel JA, Bano M, Losonczy I, Fehnel P, Kidwell WR: Presence of transforming growth factors in human breast cancer cells. Cancer Res 44: 4069–4077, 1984PubMedGoogle Scholar
  19. 19.
    Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK: Transforming growth factor β: Potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48: 3898–3904, 1988PubMedGoogle Scholar
  20. 20.
    Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-β: Biological function and chemical structure. Science 233: 532–534, 1986PubMedGoogle Scholar
  21. 21.
    Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428, 1987PubMedGoogle Scholar
  22. 22.
    Osborne CK, Ross CR, Coronado BS, Fuqua SAW, Kitten LJ: Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res Treat 11: 211–219, 1988PubMedGoogle Scholar
  23. 23.
    Picard O, Rolland Y, Poupon MF: Fibroblast-dependent tumorigenicity of cells in nude mice: Implication for implantation of metastases. Cancer Res 46: 3290–3294, 1986PubMedGoogle Scholar
  24. 24.
    Clemmons DR, Elgin RG, Han VKM, Casella SV, D'Ercole AJ, Van Wyk JJ: Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin-C/insulin like growth factor I. J Clin Invest 77: 1548–1556, 1986PubMedGoogle Scholar
  25. 25.
    Nicholson S, Sainsbury JRC, Needham GK, Chambers P, Farndon JR, Harris AL: Quantitative assays of epidermal growth factor receptor in human breast cancer: Cut-off points of clinical relevance. Int J Cancer 42: 36–41, 1988PubMedGoogle Scholar
  26. 26.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987PubMedGoogle Scholar
  27. 27.
    Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB: Type β transforming growth factor: A bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 82: 119–123, 1985PubMedGoogle Scholar
  28. 28.
    Tucker RF, Volkenaut ME, Branum EL, Moses HL: Comparison of intra- and extracellular transforming growth factors from nontransformed and chemically transformed mouse embryo cells. Cancer Res 43: 1581–1586, 1983PubMedGoogle Scholar
  29. 29.
    Massagué J: The TGF-β family of growth and differentiation factors. Cell 49: 437–438, 1987PubMedGoogle Scholar
  30. 30.
    Arteaga CL, Kitten L, Coronado E, Jacobs S, Kull F, Osborne CK: Blockade of the type I somatomedin receptor inhibits growth of estrogen receptor negative human breast cancer cells in athymic mice (Abstract). Proc 70th Annual Meeting Endocr Soc 191: 683, 1988Google Scholar
  31. 31.
    Rohlik QT, Adams D, Kull Jr FC, Jacobs S: An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells ina tissue culture. Biochem Biophys Res Commun 149: 276–281, 1987PubMedGoogle Scholar
  32. 32.
    Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002–1007, 1984PubMedGoogle Scholar
  33. 33.
    Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 823–826, 1985Google Scholar
  34. 34.
    Hanauske AR, Arteaga CL, Clark GM, Buchok J, Marshall M, Hazarika P, Pardue RL, Von Hoff DD: Determination of transforming growth factor activity in effusions from cancer patients. Cancer 61: 1832–1837, 1988PubMedGoogle Scholar
  35. 35.
    Arteaga CL, Hanauske A-R, Clark GM, Osborne CK, Hazarika P, Pardue RL, Von Hoff DD: Immunoreactive alpha transforming growth factor (IraTGF) activity in effusions from cancer patients: A marker of tumor burden and patient prognosis. Cancer Res 48: 5023–5028, 1988PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • C. Kent Osborne
    • 1
  • Carlos L. Arteaga
    • 1
  1. 1.Department of Medicine/OncologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations